Evolving Strategies for Cholesterol Management and Atherosclerotic Cardiovascular Disease Risk Reduction

EP. 1: Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

EP. 2: Risk Enhancing Factors in ASCVD
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

EP. 3: Impact of Lipid Lowering on Risk for ASCVD
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

EP. 4: Personalized Treatment for Patients with ASCVD
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

EP. 5: Achievement of Goals in ASCVD
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

EP. 6: Achievement of LDL-C Goals in the Real World
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

EP. 7: Use of Statins in Management of Hypercholesterolemia
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

EP. 8: Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

EP. 9: Lipid Lowering Agents Beyond Statins: Bempedoic Acid
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

EP. 10: Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

EP. 11: Guideline Recommendations for Lipid Lowering
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

EP. 12: Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

EP. 13: Managing ASCVD in Patients With Statin Intolerance
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

EP. 14: The Role of Combination Therapy in Hypercholesterolemia
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

EP. 15: Emerging Therapies for Hypercholesterolemia
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

EP. 16: Multidisciplinary/Team Based Approach for Lipid Management
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

EP. 17: Barriers and Solutions for Lipid Management in Clinical Practice
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

EP. 18: Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD
ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.